372,251 Shares in CeriBell (NASDAQ:CBLL) Acquired by Federated Hermes Inc.

Federated Hermes Inc. acquired a new position in shares of CeriBell (NASDAQ:CBLL - Free Report) in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund acquired 372,251 shares of the company's stock, valued at approximately $9,634,000. Federated Hermes Inc. owned 1.04% of CeriBell as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in CBLL. Rhumbline Advisers acquired a new position in shares of CeriBell during the 4th quarter worth about $320,000. Bank of New York Mellon Corp acquired a new position in CeriBell during the fourth quarter valued at approximately $628,000. Charles Schwab Investment Management Inc. bought a new stake in CeriBell in the fourth quarter valued at approximately $2,500,000. PNC Financial Services Group Inc. bought a new position in shares of CeriBell during the fourth quarter worth $47,000. Finally, Vanguard Group Inc. bought a new stake in shares of CeriBell in the 4th quarter valued at $18,015,000.

CeriBell Price Performance

NASDAQ:CBLL traded down $0.23 on Tuesday, hitting $14.65. 170,020 shares of the company's stock were exchanged, compared to its average volume of 265,421. The business has a 50-day simple moving average of $20.88. CeriBell has a 52 week low of $10.01 and a 52 week high of $32.75.

CeriBell (NASDAQ:CBLL - Get Free Report) last issued its earnings results on Tuesday, February 25th. The company reported ($0.40) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.32) by ($0.08). The firm had revenue of $18.53 million for the quarter, compared to the consensus estimate of $17.55 million. On average, analysts anticipate that CeriBell will post -2.46 earnings per share for the current fiscal year.

Remove Ads

Wall Street Analysts Forecast Growth

Several equities research analysts have issued reports on the company. Canaccord Genuity Group restated a "buy" rating and issued a $33.00 price target on shares of CeriBell in a report on Wednesday, February 26th. LADENBURG THALM/SH SH started coverage on shares of CeriBell in a report on Friday, April 4th. They set a "buy" rating and a $32.00 price objective on the stock. Seven equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock currently has a consensus rating of "Buy" and a consensus price target of $32.50.

About CeriBell

We are a commercial-stage medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. We have developed the Ceribell System, a novel, point-of-care electroencephalography (“EEG”) platform specifically designed to address the unmet needs of patients in the acute care setting.